Nimotuzumab increases chemosensitivity of human lung adenocarcinoma cell lines to docetaxel

Oncology Research

Volumn 20, Issue 1, 2012, Pages 39-47

  Song, Hai Zhu ^a   Yi, Jun ^a   Chen, Jing ^a   Chen, Long Bang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Chemoresistance; Docetaxel (DTX); Epidermal growth factor receptor (EGFR); Lung adenocarcinoma; Nimotuzumab (h R3)

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; NIMOTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA CELL; CELL ASSAY; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 84865513186     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504012X13425470196218     Document Type: Article

References (41)

1. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 61:69-90; 2011.
2. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics. CA Cancer J. Clin. 60:277-300; 2010.
3. Sher, T.; Dy, G. K.; Adjei, A. A. Small cell lung cancer. Mayo Clin. Proc. 83:355-367; 2008.
4. Ettinger, D. S.; Akerley, W.; Bepler, G.; Chang, A.; Cheney, R. T.; Chirieac, L. R.; D'Amico, T. A.; Demmy, T. L.; Feigenberg, S. J.; Figlin, R. A.; Govindan, R.; Grannis, Jr., F. W.; Jahan, T.; Jahanzeb, M.; Kessinger, A.; Komaki, R.; Kris, M. G.; Langer, C. J.; Le, Q. T.; Martins, R.; Otterson, G. A.; Patel, J. D.; Robert, F.; Sugarbaker, D. J.; Wood, D. E. Non-small cell lung cancer. J. Natl. Compr. Cancer Netw. 6:228-269; 2008.
5. Ettinger, D. S.; Akerley, W.; Bepler, G.; Blum, M. G.; Chang, A.; Cheney, R. T.; Chirieac, L. R.; D'Amico, T. A.; Demmy, T. L.; Ganti, A. K.; Govindan, R.; Grannis, Jr., F. W.; Jahan, T.; Jahanzeb, M.; Johnson, D. H.; Kessinger, A.; Komaki, R.; Kong, F. M.; Kris, M. G.; Krug, L. M.; Le, Q. T.; Lennes, I. T.; Martins, R.; O'Malley, J.; Osarogiagbon, R. U.; Otterson, G. A.; Patel, J. D.; Pisters, K. M.; Reckamp, K.; Riely, G. J.; Rohren, E.; Simon, G. R.; Swanson, S. J.; Wood, D. E.; Yang, S. C.; Non-small cell lung cancer. J. Natl. Compr. Cancer Netw. 8:740-801; 2010.
6. Akashi, Y.; Okamoto, I.; Iwasa, T.; Yoshida, T.; Suzuki, M.; Hatashita, E.; Yamada, Y.; Satoh, T.; Fukuoka, M.; Ono, K.; Nakagawa, K. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br. J. Cancer 98:749-755; 2008.
7. Akimoto, T.; Hunter, N. R.; Buchmiller, L.; Mason, K.; Ang, K. K.; Milas, L. Inverse Relationship between Epidermal Growth Factor Receptor Expression and Radiocurability of Murine Carcinomas. Clin Cancer Res 5: 2884-2890;1999 [PubMed: 10537357]
8. Liang, K.; Ang, K. K.; Milas, L.; Hunter, N.; Fan, Z. The epidermal growth factor receptor mediates radioresistance. Int. J. Radiat. Oncol. Biol. Phys. 57:246-254; 2003.
9. Burdak-Rothkamm, S.; Rübe, C. E.; Nguyen, T. P.; Ludwig, D.; Feldmann, K.; Wiegel, T.; Rübe, C. Radio-sensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa). Strahlenther Onkol. 181:197-204; 2005.
10. Perez-Soler, R. HER1/EGFR targeting: Refining the strategy. Oncologist 9:58-67; 2004.
11. West, C. M.; Joseph, L.; Bhana, S. Epidermal growth factor receptor-targeted therapy. Br. J. Radiol. 81:S36-544; 2008.
12. Levitzki, A. EGF receptor as a therapeutic target. Lung Cancer 41:S9-14; 2003.
13. Mendelsohn, J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20:1S-13S; 2002.
14. Giaccone, G.; Herbst, R. S.; Manegold, C.; Scagliotti, G.; Rosell, R.; Miller, V.; Natale, R. B.; Schiller, J. H.; Von Pawel, J.; Pluzanska, A.; Gatzemeier, U.; Grous, J.; Ochs, J. S.; Averbuch, S. D.; Wolf, M. K.; Rennie, P.; Fandi, A.; Johnson, D. H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J. Clin. Oncol. 22: 777-784; 2004.
15. Pirker, R.; Pereira, J. R.; Szczesna, A.; von Pawel, J.; Krzakowski, M.; Ramlau, R.; Vynnychenko, I.; Park, K.; Yu, C. T.; Ganul, V.; Roh, J. K.; Bajetta, E.; O'Byrne, K.; de Marinis, F.; Eberhardt, W.; Goddemeier, T.; Emig, M.; Gatzemeier, U.; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373:1525-1531; 2009.
16. Steiner, P.; Joynes, C.; Bassi, R.; Wang, S.; Tonra, J. R.; Hadari, Y. R.; Hicklin, D. J. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin. Cancer Res. 13: 1540-1551; 2007.
17. Gridelli, C.; Maione, P.; Ferrara, M. L.; Rossi, A. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist 14:601-611; 2009.
18. Berger, C.; Krengel, U.; Stang, E.; Moreno, E.; Helene Madshus, I. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations. J. Immunother. 34:550-555; 2011.
19. Garrido, G.; Tikhomirov, I. A.; Rabasa, A.; Yang, E.; Gracia, E.; Iznaga, N.; Fernández, L. E.; Crombet, T.; Kerbel, R. S.; Pérez, R. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain anti-body clinical profile. Cancer Biol. Ther. 11:373-382; 2011.
20. Talavera, A.; Friemann, R.; Gómez-Puerta, S.; Martinez-Fleites, C.; Garrido, G.; Rabasa, A.; López-Requena, A.; Pupo, A.; Johansen, R. F.; Sánchez, O.; Krengel, U.; Moreno, E. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 69:5851-5859; 2009.
21. Boland, W. K.; Bebb, G. Nimotuzumab: A novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin. Biol. Ther. 9:1199-1206; 2009.
22. Ledón, N.; Casacó, A.; Casanova, E.; Beausoleil, I. Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models. Placenta 32:531-534; 2011.
23. Diaz Miqueli, A.; Blanco, R.; Garcia, B.; Badia, T.; Batista, A. E.; Alonso, R.; Montero, E. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt) 26:423-431; 2007.
24. Crombet-Ramos, T.; Rak, J.; P'rez, R.; Viloria-Petit, A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int. J. Cancer 101:567-575; 2002.
25. Bebb, G.; Smith, C.; Rorke, S.; Boland, W.; Nicacio, L.; Sukhoo, R.; Brade, A. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother. Pharmacol. 67:837-845; 2011.
26. Choi, H. J.; Sohn, J. H.; Lee, C. G.; Shim, H. S.; Lee, I. J.; Yang, W. I.; Kwon, J. E.; Kim, S. K.; Park, M. S.; Lee, J. H.; Kim, J. H. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer 71:55-59; 2011.
27. Rui, W.; Bing, F.; Hai-Zhu, S.; Wei, D.; Long-Bang, C. Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J. Cell. Mol. Med. 14:206-214; 2010.
28. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440-446; 2010.
29. Diaz Miqueli, A.; Rolff, J.; Lemm, M.; Fichtner, I.; Perez, R.; Montero, E. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br. J. Cancer 100:950-958; 2009.
30. Basavaraj, C.; Sierra, P.; Shivu, J.; Melarkode, R.; Montero, E.; Nair, P. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR. Cancer Biol. Ther. 10(7):673-681; 2010.
31. Yang, Q. Y.; Shen, D.; Sai, K.; Mu, Y. G.; Jiang, X. B.; Zhang, X. H.; Chen, Z. P. Nimotuzumab in combination with chemotherapy for patients with malignant gliomas. Zhonghua Zhong Liu Za Zhi 33:232-235; 2011.
32. Rodriguez, M. O.; Rivero, T. C.; del Castillo Bahi, R.; Muchuli, C. R.; Bilbao, M. A.; Vinageras, E. N.; Alert, J.; Galainena, J. J.; Rodriguez, E.; Gracias, E.; Mulen, B.; Wilkinson, B.; de Armas, E. L.; Perez, K.; Pineda, I.; Frometa, M.; Leonard, I.; Mullens, V.; Viada, C.; Luaces, P.; Torres, O.; Iznaga, N.; Crombet, T. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol. Ther. 9:343-349; 2010.
33. Basavaraj, C.; Sierra, P.; Shivu, J.; Melarkode, R.; Montero, E.; Nair, P. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR. Cancer Biol. Ther. 10: 673-681; 2010.
34. Crombet, T.; Osorio, M.; Cruz, T.; Roca, C.; del Castillo, R.; Mon, R.; Iznaga-Escobar, N.; Figueredo, R.; Koropatnick, J.; Renginfo, E.; Fernández, E.; Alvárez, D.; Torres, O.; Ramos, M.; Leonard, I.; Pérez, R.; Lage, A. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiother apy in the treatment of locally advanced head and neck cancer patients. J. Clin. Oncol. 22:1646-1654; 2004.
35. Sun, H.; Geng, J.; Chen, L. Screening differential expression of docetaxel-resistance related genes of human lung adenocarcinoma cell line SPC-A1 by cDNA microarray. Zhongguo Fei Ai Za Zhi 10:356-361; 2007.
36. Agaev, B.; Muslimov, G.; Iagublu, V.; Ge?drikh, B. Effect of EGFR (epidermal growth factor receptor) inhibitors on apoptosis and cell proliferation in pancreatic cancer. Eksp Klin Gastroenterol 2:84-90; 2008 [PubMed: 19145871]
37. Herbst, R. S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 59:21-26; 2004.
38. Lurje, G.; Lenz, H. J. EGFR signaling and drug discovery. Oncology 77:400-410; 2009.
39. Zahorowska, B.; Crowe, P. J.; Yang, J. L. Combined therapies for cancer: A review of EGFR-targeted monotherapy and combination treatment with other drugs. J. Cancer Res. Clin. Oncol. 135:1137-1148; 2009.
40. Goel, S.; Hidalgo, M.; Perez-Soler, R. EGFR inhibitor-mediated apoptosis in solid tumors. J. Exp. Ther. Oncol. 6:305-320; 2007.
41. Muslimov, G. F. Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma. Bull. Exp. Biol. Med. 145:535-538; 2008.